Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3444977 | 1.00 | ALDH1A1 (0.61) | ALDH1A1GAATDP1POLBL3MBTL1 | |
| SCHEMBL1237351 | 1.00 | ALDH1A1 (0.61) | ALDH1A1GAATDP1POLBL3MBTL1 | |
| SCHEMBL16417482 | 0.90 | ALDH1A1 (0.50) | ALDH1A1GAATDP1POLBL3MBTL1 | |
| SCHEMBL8283046 | 0.87 | CASP3 (0.50) | ALDH1A1GAATDP1POLBL3MBTL1 | |
| SCHEMBL21226294 | 0.86 | ALDH1A1 (0.47) | ALDH1A1GAATDP1POLBL3MBTL1 | |
| SCHEMBL16414776 | 0.85 | LMNA (0.50) | ALDH1A1GAATDP1POLBL3MBTL1 | |
| SCHEMBL27903461 | 0.85 | TDP1 (0.49) | ALDH1A1GAATDP1POLBL3MBTL1 | |
| SCHEMBL21449400 | 0.85 | ALDH1A1 (0.46) | ALDH1A1GAATDP1POLBL3MBTL1 | |
| SCHEMBL1239670 | 0.84 | TDP1 (0.62) | ALDH1A1GAATDP1POLBL3MBTL1 | |
| SCHEMBL1239675 | 0.84 | TDP1 (0.62) | ALDH1A1GAATDP1POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3044226-B1 | ARYL ETHER-BASE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-09-06 | — | — | EP | disclosed |
| US-20160222021-A1 | ARYL ETHER-BASE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-04 | — | — | US | disclosed |
| EP-3044226-A1 | ARYL ETHER-BASE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2822952-B1 | ARYL ETHER-BASE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-06 | — | — | EP | disclosed |
| WO-2015038112-A1 | ARYL ETHER-BASE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-19 | — | — | WO | disclosed |
| US-8969564-B2 | Aryl ether-base kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-03 | — | — | US | disclosed |
| EP-2822952-A1 | ARYL ETHER-BASE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2015-01-14 | — | — | EP | disclosed |
| US-20140179725-A1 | Aryl Ether-Base Kinase Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-06-26 | — | — | US | disclosed |
| US-8703953-B2 | Aryl ether-base kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-04-22 | — | — | US | disclosed |
| WO-2013134036-A1 | ARYL ETHER-BASE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-09-12 | — | — | WO | disclosed |
| US-20090281310-A1 | 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde; inhibits production of A beta 40 and A beta 42 from amyloid precursor protein ; Alzheimer's disease and Down syndrome | EISAI R&D MANAGEMENT CO., LTD. | 2009-11-12 | — | — | US | disclosed |
| US-20090270445-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-7514566-B2 | Thiazole compounds and methods of use | AMGEN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1981884-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS | Amgen, Inc (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20080070902-A1 | Cinnamide Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
| WO-2007084391-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B ( PKB) INHIBITORS | AMGEN INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | disclosed |
| EP-1757591-A1 | CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | EISAI CO., LTD. | 2006-01-05 | — | — | US | disclosed |
| US-4235892-A | AROMATIC ANTIBIOTICS | Schering Corporation, Patent Dept. (US) | 1980-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179725-A1 | Aryl Ether-Base Kinase Inhibitors | AAK1, NCK1, ADCK1 | ALDH1A1 3028/4885GAA 3155/4885TDP1 1874/4885 |
| US-20090281310-A1 | 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde; inhibits production of A beta 40 and A beta 42 from amyloid precursor protein ; Alzheimer's disease and Down syndrome | APP, PSEN1, BACE1 | ALDH1A1 451/4885GAA 1184/4885TDP1 614/4885 |
| US-20160222021-A1 | ARYL ETHER-BASE KINASE INHIBITORS | AAK1, NCK1, ADCK1 | ALDH1A1 3028/4885GAA 3155/4885TDP1 1874/4885 |
| US-20080070902-A1 | Cinnamide Compound | C1S, CCR1, CNR1 | ALDH1A1 58/4885GAA 1517/4885TDP1 4661/4885 |
| US-20090270445-A1 | Thiazole compounds and methods of use | MTOR, JAK2, TK2 | ALDH1A1 2019/4885GAA 2168/4885TDP1 2716/4885 |
| US-20070173506-A1 | Thiazole compounds and methods of use | MTOR, JAK2, PCK2 | ALDH1A1 2061/4885GAA 2275/4885TDP1 3338/4885 |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | PSEN1, APP, BACE1 | ALDH1A1 1375/4885GAA 3067/4885TDP1 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.